Scholarlink

<p>Cholera, caused by <i>Vibrio cholerae</i>, remains a significant global health threat, with the O1 serotype being the predominant cause of recent global outbreaks. Although conjugate vaccines against <i>V. cholerae</i> have been developed via chemical methods, the feasibility of applying novel biosynthetic approaches remains uncertain due to the special structure of its O-polysaccharide, which should be recognized by oligosaccharyltransferases. Here, we successfully established an oligosaccharyltransferase PglL-based glycosylation system in an engineered <i>V. cholerae</i> strain to biosynthesize a nanoscale conjugate vaccine, NP-OPS<sub>Vc(I)</sub>. The carrier NP was designed by fusing the cholera toxin B subunit (CTB) with a trimer-forming protein (Tri), which could self‑assemble into a nanoparticle during expression. The resulting glycoprotein exhibited high purity, stability, and retained GM1-binding capacity. We found that the size of NP-OPS<sub>Vc(I)</sub> and its GM1 receptor targeting both contribute to a potent humoral immune response, while its efficient delivery is additionally associated with the induction of intestinal mucosal immunity. In mouse models, the NP-OPS<sub>Vc(I)</sub> demonstrated a favorable safety profile and elicited substantially stronger systemic and mucosal immune responses than conventional conjugates, providing great protection against lethal <i>V. cholerae</i> challenge even at a 10‑fold lower dose without requiring an adjuvant. Furthermore, the immune responses were confirmed in non-human primates, supporting its potential for clinical translation. This work not only developed a novel highly effective candidate vaccine against <i>V. cholerae</i> but also significantly expanded the application scope of the PglL-based platform technology, establishing it as a versatile and broadly applicable enzymatic toolkit for vaccine development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biosynthesis of a nanoscale Vibrio cholerae conjugate vaccine elicits potent immunity through size and receptor effects

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • Kangfeng Wang,
  • Jing Huang,
  • Juntao Li,
  • Zhenshi Li,
  • Lingli Chen,
  • Canran Liu,
  • Xue Yan,
  • Yuqing Jiang,
  • Yan Guo,
  • Peng Sun,
  • Jun Wu,
  • Li Zhu,
  • Hengliang Wang,
  • Chao Pan

摘要

Cholera, caused by Vibrio cholerae, remains a significant global health threat, with the O1 serotype being the predominant cause of recent global outbreaks. Although conjugate vaccines against V. cholerae have been developed via chemical methods, the feasibility of applying novel biosynthetic approaches remains uncertain due to the special structure of its O-polysaccharide, which should be recognized by oligosaccharyltransferases. Here, we successfully established an oligosaccharyltransferase PglL-based glycosylation system in an engineered V. cholerae strain to biosynthesize a nanoscale conjugate vaccine, NP-OPSVc(I). The carrier NP was designed by fusing the cholera toxin B subunit (CTB) with a trimer-forming protein (Tri), which could self‑assemble into a nanoparticle during expression. The resulting glycoprotein exhibited high purity, stability, and retained GM1-binding capacity. We found that the size of NP-OPSVc(I) and its GM1 receptor targeting both contribute to a potent humoral immune response, while its efficient delivery is additionally associated with the induction of intestinal mucosal immunity. In mouse models, the NP-OPSVc(I) demonstrated a favorable safety profile and elicited substantially stronger systemic and mucosal immune responses than conventional conjugates, providing great protection against lethal V. cholerae challenge even at a 10‑fold lower dose without requiring an adjuvant. Furthermore, the immune responses were confirmed in non-human primates, supporting its potential for clinical translation. This work not only developed a novel highly effective candidate vaccine against V. cholerae but also significantly expanded the application scope of the PglL-based platform technology, establishing it as a versatile and broadly applicable enzymatic toolkit for vaccine development.